

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Elfatih Elzein et al.

Confirmation No.: 1980

Serial No.: 10/729,499

Group Art Unit: 1624

Filing Date: December 5, 2003

Examiner: Not Assigned

Title: SUBSTITUTED HETEROCYCLIC COMPOUNDS

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT AND CERTIFICATION UNDER 37 CFR § 1.97(e)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

37 CFR § 1.98(d).

Sir:

This is a Supplemental Information Disclosure Statement submitted for the Examiner's consideration. Applicants respectfully request that the Examiner review and make of record the references identified below. The references listed below are being submitted to the Office promptly after they have become known to applicants and are being submitted prior to the final determination on patentability by the Office. X The references listed below were cited in an International (PCT) Search Report dated May 28, 2004, for the PCT application corresponding to the above-identified U.S. patent application. A copy of the Search Report, including an indication of the purported relevance of the cited references, is enclosed. Copies of the references are also submitted herewith, excluding U.S. patents and/or publications as the subject application was filed after June 30, 2003. The references identified below were disclosed in parent application Serial No. . As such, copies of the references are not included pursuant to the provisions of

A PTO-1449 form listing the references accompanies this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record. The references are as follows:

F	OREIGN PATENT DOCUMENTS	
Document No.	Publication Date	Country
WO 03/008411	January 30, 2003	WO
WO 01/62744	August 30, 2001	WO
WO 01/62711	August 30, 2001	WO

As the subject application was filed after June 30, 2003, copies of the U.S. patents and/or publications disclosed in this Information Disclosure Statement are not required and, therefore, are not included.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any of the above references constitutes prior art to the present application within the meaning of 35 USC § 102.

As applicants have not yet received a first Action on the merits, no fee is required for filing this Information Disclosure Statement. If, however, the PTO finds that for some reason a fee is found to be necessary, our Deposit Account No. 50-1789 may be charged therefor.

Respectfully submitted,

By:

I/Elin Hartrum

Registration No. 43,663

CV Therapeutics, Inc. 3172 Porter Drive

Palo Alto, California 94304 Telephone: (650) 384-8755 Facsimile: (650) 475-0359

-							
				Complete if Known			
Substitute for	form 1449A/PTO			Application Number 10/729,499			
INFORMATION DISCLOSURE				Filing Date	December 5, 2003		
STATEMENT BY APPLICANT				First Named Inventor	Elfatih Elzein		
				Art Unit			
	(use as many sh	ieets as necess	ary)	Examiner Name			
Sheet	1	of	1	Attorney Docket Number	02-0175		

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Document No.	Issue Date or Publication Date	Name of Patentee or Applicant of Cited Document	Class	Subclass	Filing Date if Appropriate
		PE					
		10 0					
		2002 11					
		2 5 2004 W					
		TRADEMORE				Ì	
		TRADEM					
	-						
					1	1	
						<b>†</b>	

		FOREIG	N PATENT DOCUN	MENTS			
Examiner Initials*	Cite No.	Foreign Patent Document No.	Publication Date	Country	Class	Subclass	Т
		WO 03/008411	Jan 2003	WO			
		WO 01/62744	August 2001	WO			
		WO 01/62711	Aug., 2001	WO			

OTHER DOCUMENTS — NONPATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), Title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т		
			+		

Examiner	Date	
Signature	Considere	1

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.